- Momordin Ic
-
- $30.00
-
2026-06-02
- CAS:96990-18-0
- Purity: 99.69%
- Supply Ability: 10g
- Momordin Ic
-
-
2023-02-24
- CAS:96990-18-0
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
- Momordin Ic
-
-
2023-02-24
- CAS:96990-18-0
- Min. Order: 5mg
- Purity: Analytical Standard
- Supply Ability: 10 g
|
| | MOMORDINIC Basic information |
| | MOMORDINIC Chemical Properties |
| Melting point | 238-240 °C | | Boiling point | 886.2±65.0 °C(Predicted) | | density | 1.35±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | Methanol (Slightly, Heated, Sonicated), Pyridine (Slightly) | | form | Solid | | pka | 2.75±0.70(Predicted) | | color | White to Pale Yellow | | Optical Rotation | [α]/D 12 to 17° in methanol (c=0.5 g/100mL) | | Stability: | Hygroscopic | | InChIKey | HWYBGIDROCYPOE-UAEHAXNUNA-N |
| Safety Statements | 24/25 | | WGK Germany | WGK 3 | | HS Code | 29389090 | | Storage Class | 11 - Combustible Solids |
| | MOMORDINIC Usage And Synthesis |
| Chemical Properties | Light yellow crystalline powder, soluble in methanol, derived from Kochia scoparia seeds. | | Uses | Mormodin Ic is used as an anti-cancer agent, and is shown to induce HepG2 apoptosis in a PI3K and MAPK pathway-dependant manner. | | Definition | ChEBI: Momordin ic is a triterpenoid saponin. | | Biological Activity | Potent inhibitor of SUMO-specific protease 1 (SENP1) th at increases SUMOylated proteins in PC3 cells | | in vivo | Momordin Ic (12.5, 25, 50 mg/kg, p.o.) accelerates gastrointestinal transport and inhibits gastric emptying in mice by stimulating the synthesis of serotonin (5-HT)[4].
Momordin Ic (10 mg/kg, p.o.) can inhibit ethanol induced gastric mucosal lesions in rats[5].
Momordin Ic (30 mg/kg, once a day for 14 days, p.o.) can reduce CCl4-induced hepatotoxicity in rats[6]. | Animal Model: | Male ddY mice[4]. | | Dosage: | 12.5, 25, 50 mg/kg | | Administration: | Oral gavage (p.o.) | | Result: | Accelerated gastrointestinal transit in fasted mice. |
| Animal Model: | Male Sprague-Dawley rat[5]. | | Dosage: | 10 mg/kg | | Administration: | Oral gavage (p.o.) | | Result: | Reduced the length of the lesions. |
| Animal Model: | Male Sprague–Dawley rat[6]. | | Dosage: | 30 mg/kg | | Administration: | Oral gavage (p.o.), once a day for 14 days | | Result: | Reduced serum transaminase, lactic dehydrogenase, and γ-glutamyltransferase levels in the CCl4-treated rats. |
|
| | MOMORDINIC Preparation Products And Raw materials |
|